Serendex Pharmaceuticals A/S : Major shareholding notification

Major shareholding notification from Serendex' major shareholders cf. sections 27(1) and 29(1)(3) of the Danish Securities Trading Act (in Danish: Lov o værdipapirhandel m.v.).

Reference is made to stock exchange announcements by Serendex Pharmaceuticals A/S in connection with the approved prospectus for the Rights Issue dated 10 December 2015 and the supplement prospectus for the Rights Issue dated 21 December 2015.

Pursuant to the Danish Securities Trading Act sections 27(1) and 29(1)(3) Serendex is subject to the disclosure of the following recieved information:

Lorentz Jørgensen (board member), through his wholly owned company Sorana A/S, was allocated 128,587,034 shares in the Rights Issue at a price of NOK 0.75 per share. Following the Rights Issue, Mr. Jørgensen and his related parties control 136,972,998 shares, corresponding to 83.47% of the share capital. Hence, following the Rights Issue, Mr. Jørgensen and his related parties control more than 66.7% the share capital and voting rights.

For download 06 January 2016_Major shareholding notification

For further information, please contact :

Søren Bech Justesen, CFO
Mobile [phone]
E-mail: [e-mail]

About Serendex Pharmaceuticals A/S

Serendex Pharmaceuticals develops drugs to treat severe respiratory conditions such as PAP (pulmonary alveolar proteinosis) and ARDS (acute respiratory distress syndrome). These conditions are acute or chronic and have no existing medical treatment. All Serendex drugs are inhaled or induced to the lungs of the patient. This improves the risk/efficacy ratio of the drug and treatment. Serendex has obtained orphan drug designation (ODD) for several indications in both Europe and USA. The company's sole business focus is drug repositioning, i.e. finding new indications and administration routes for existing drugs. Serendex Pharmaceuticals is listed on Oslo Axess. Please visitwww.serendex.com to learn more.